NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

A型肝炎疫苗的全球市場:2020年∼2027年

Global Hepatitis A Vaccine Market, Size, Share, Opportunities and Forecast, 2020-2027

出版商 DataM Intelligence 商品編碼 991641
出版日期 內容資訊 英文 180 Pages
商品交期: 約2個工作天內
價格
A型肝炎疫苗的全球市場:2020年∼2027年 Global Hepatitis A Vaccine Market, Size, Share, Opportunities and Forecast, 2020-2027
出版日期: 2021年04月03日內容資訊: 英文 180 Pages
簡介

促進A型肝炎疫苗市場成長的主要原因,是A型肝炎的盛行率增加。還有A型肝炎的病例數增加,政府和醫療機關提高這個疾病相關認識在,管理風險容易發生的地區導入疫苗接種的推動的階段。

本報告提供全球A型肝炎疫苗市場相關調查分析,產業分析,各市場區隔的市場分析,競爭情形,主要企業等相關的系統性資訊。

目錄

第1章 全球A型肝炎疫苗市場調查手法與調查範圍

第2章 全球A型肝炎疫苗市場:市場定義與市場概要

第3章 全球A型肝炎疫苗市場:摘要整理

第4章 全球A型肝炎疫苗市場:市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 影響分析

第5章 全球A型肝炎疫苗市場:產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價值鏈分析
  • PEST分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求
  • 專利趨勢

第6章 全球A型肝炎疫苗市場:COVID-19分析

  • 對市場的COVID-19分析
  • COVID-19的價格趨勢
  • 供需頻譜
  • 大流行時的市場相關的政府舉措
  • 製造商策略性舉措
  • 結論

第7章 全球A型肝炎疫苗市場:各產品類型

  • 簡介
  • 各產品類型市場區隔的市場規模分析、與前一年同期比較成長率分析
  • 各產品類型市場區隔的市場魅力指數
    • 不活化疫苗
    • 減毒活病毒疫苗

第8章 全球A型肝炎疫苗市場:各用途

  • 簡介
  • 各用途市場區隔的市場規模分析、與前一年同期比較成長率分析
  • 各用途市場區隔的市場魅力指數
    • 政府機關
    • 民間部門
    • 其他

第9章 全球A型肝炎疫苗市場:各地區

  • 簡介
  • 各地區的市場規模分析、與前一年同期比較成長率分析
  • 各地區的市場魅力指數
  • 北美
  • 歐洲
  • 南美
  • 亞太地區
  • 中東、非洲

第10章 全球A型肝炎疫苗市場:競爭情形

  • 競爭模式
  • 市場定位/佔有率分析
  • M&A分析

第11章 全球A型肝炎疫苗市場:企業簡介

  • GlaxoSmithKline
  • Merck & Co., Inc.
  • Sanofi
  • Sinovac
  • Zhejiang Pukang
  • Changchun Institute of Biological
  • KM Biologics
  • IMBCA
  • ChangSheng
  • Convac等

第12章 全球A型肝炎疫苗市場:重要考察

第13章 全球A型肝炎疫苗市場:DataM Intelligence

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Global Hepatitis A Vaccine Market Is Segmented By Product Type (Inactivated vaccine, Live  Attenuated Vaccine), By Application Segment (Government Institution, Private Sector, Other), And By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Share, Size, Outlook, and Opportunity Analysis, 2020-2027

Market Overview

The Hepatitis A Vaccine Market is expected to grow at a high CAGR of 2.8% during the forecasting period (2020-2027).

Hepatitis A Vaccine is a vaccine that prevents hepatitis A. The disease is a liver disorder caused by the hepatitis A virus leading from mild to severe illness. The Hepatitis A Virus (HAV) is transferred through either ingestion of contaminated food and water or direct contact with an infectious person. The disease has a propensity for cyclic reappearances, which occurs in epidemics globally. The Antibodies introduced in response to the disease lasts through life and protects against recurrence of infection, the best way for which is through vaccination. It is given in two doses injected six months apart.

Source: DataM Intelligence Analysis (2019)

Market Dynamics

The major factors propelling the growth of the Hepatitis A Vaccine market are the increasing prevalence of hepatitis A globally, which leads to increasing concerns for vaccination. The rise in the number of Hepatitis A cases propels the national governments and healthcare organizations to introduce steps to increase awareness about the disease and manage vaccination drives in the risk-prone areas. Further continuous efforts by the market players to promote Hepatitis A vaccines drive the market growth.

Increasing Government Initiatives for Prevention

Hepatitis A Vaccine is used to submerge the rising cases for Hepatitis A. As per the Center for Disease Control, in 2018, the U.S. reported a total of 12,474 hepatitis A cases, and the organization estimated the actual number of cases reported in the year to 24,900 owing to the undiagnosed cases. This has propelled governments to increase their efforts for awareness, diagnosis, treatment, and vaccination. As per the World Health Organization, as of May 2019, the introduction of Hepatitis A vaccine in routine immunization of children in specific risk groups was used or planed by a total of 34 countries across the globe. According to the WHO, approximately 90.0% of children are infected with the hepatitis A virus before 10 years in developed countries with inadequate sanitary conditions and sanitation habits. Government vaccination programs are propelling the worldwide market for hepatitis A vaccines in developing countries.

Lack of awareness among the population

Lack of awareness concerning the Hepatitis A disease among individuals is a key factor expected to curtail the global market's growth over the forecast period. Moreover, resistance among the population for diagnosis also obstructs market growth.

COVID-19 Impact Analysis

The outbreak of COVID-19 has negatively impacted the growth of the Hepatitis A Vaccine market globally. The disruption in the supply chain has majorly impacted the growth of the market amidst the pandemic. The escalated focus on COVID-19 vaccine development, product type, and distribution has led to de-escalation in Hepatitis A vaccines. Therefore, the COVID-19 pandemic has hampered the market value of the Hepatitis A Vaccine market in 2020.

Hepatitis A Vaccine Market Segment Analysis

The Hepatitis A Vaccine market has been classified into Inactivated vaccine and a Live attenuated vaccine based on the Product Type type.

Inactivated vaccine segment is projected to be the dominant segment in the market during the forecast period.

Inactivated vaccine dominated the global market in 2019, also it is expected to present considerable growth shortly. Inactivated Vaccines are safe and highly functional. A two-dose schedule is traditionally recommended, particularly for travelers at significant risk of contracting hepatitis A and immunocompromised individuals. However, with a single dosage, equivalent efficacy has been achieved in stable people. This is expected to propel segmental growth soon.

Hepatitis A Vaccine is segmented based on Application, which includes Government Institution, Private Sector and Other.

Government Institution is expected to dominate the Hepatitis A Vaccine market.

Government institutions held the dominant position in the global market during the forecast period. Patients depend on public healthcare facilities for diagnosis and proper vaccination of Hepatitis A, supporting the segment growth during the forecast period. Moreover, the surging government programs offering vaccination drives are expected to project a considerable CAGR during the forecast period.

Source: DataM Intelligence Analysis (2019)

Geographical Analysis

Based on geography, the study analyzes the Hepatitis A Vaccine market globally, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

Asia-Pacific is expected to dominate the global Hepatitis A Vaccine market.

Asia-Pacific held a dominant position in the global Hepatitis A Vaccine market in 2019. In Asia-Pacific, China is expected to represent considerable growth during the forecast period. As in China, the live attenuated Hepatitis A Vaccine is becoming a favorable element to tackle the disease. Moreover, Europe is expected to represent significant growth in terms of value during the forecast period. The easy availability of vaccines at a comparatively lower cost is expected to propel market growth across the region. Hepatitis A Vaccine market for the Asia Pacific is expected to observe rapid growth over the forecast period, backed by government policies and programs, especially in India and China. Moreover, the rise in the pediatric population and increased awareness about vaccination results in increasing demand for Hepatitis A Vaccine in emerging economies, such as India and China, which is expected to augment Asia Pacific's growth Hepatitis A Vaccine market.

Source: DataM Intelligence Analysis (2019)

Hepatitis A Vaccine Market Competitive Landscape

The Hepatitis A Vaccine market is highly competitive, owing to the presence of major market players. The key Hepatitis A Vaccine players contributing to the global market's growth include GlaxoSmithKline, Merck & Co. Inc., Sanofi, Sinovac, Zhejiang Pukang, Changchun Institute of Biological, KM Biologics, IMBCA, ChangSheng, Convac, among others. The major players are adopting new expansion strategies for global growth in the Hepatitis A Vaccine market.  

HAVRIX (GlaxoSmithKline):

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases, including hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastrointestinal, and skin health categories. The CET segment refers to the management of business activities. HAVRIX is a vaccine suitable for successful immunization of hepatitis A virus diseases (HAV). HAVRIX is licensed for use in people over the age of 12 months. At least 2 weeks before the planned exposure to HAV, primary immunization should be administered. The other Product Types offered by the company include Hepatyrix and Ambirix.

Product Type Portfolio: The company's portfolio comprises a range of vaccines which includes Hepatitis A, Hepatitis B, Hepatitis C, among others

Why Purchase the Report?

Visualize the Hepatitis A Vaccine market segmentation composition by product type, application, and region, highlighting the critical commercial assets and players.

Identify commercial opportunities in the Hepatitis A Vaccine market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of Hepatitis A Vaccine market - level 3 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product Type mapping in excel for the key Product Type of all major market players

The global Hepatitis A Vaccine market report would provide access to an approx. 51 market data table, 45 figures and 221 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Related Topic's

Hepatitis Diagnostic Testing Market

Vaccines Market

Table of Contents

Table of Contents

Hepatitis A Vaccine Market Methodology and Scope

Research Methodology

Research Objective and Scope of the Report

Hepatitis A Vaccine Market - Market Definition and Overview

Hepatitis A Vaccine Market - Executive Summary

Market Snippet by Product Type 

Market Snippet by Application

Market Snippet by Region

Hepatitis A Vaccine Market - Market Dynamics

Market Impacting Factors

Drivers

Increasing Government Initiatives for Prevention

Increasing prevalence of Hepatitis A disease in poor countries

Restraints:

Lack of awareness among population

Impact Analysis

Hepatitis A Vaccine Market - Industry Analysis

Porter's Five Forces Analysis

Supply Chain Analysis

Value Chain Analysis

PEST Analysis

Pricing Analysis

Regulatory Analysis

Reimbursement Analysis

Unmet Needs

Patent Trends

Hepatitis A Vaccine Market - COVID-19 Analysis

Analysis of Covid-19 on the Market

Before COVID-19 Market Scenario

Present COVID-19 Market Scenario

After COVID-19 or Future Scenario

Pricing Dynamics Amid Covid-19

Demand-Supply Spectrum

Government Initiatives Related to the Market During Pandemic

Manufacturers Strategic Initiatives

Conclusion 

Hepatitis A Vaccine Market - By Product Type  

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type 

Market Attractiveness Index, By Product Type

Inactivated vaccine

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

Live Attenuated Vaccine

Hepatitis A Vaccine Market - By Application

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment

Market Attractiveness Index, By Application Segment

Government Institution*

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

Private Sector

Other

Hepatitis A Vaccine Market - By Region

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

Market Attractiveness Index, By Region

North America

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type 

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

U.S.

Canada

Mexico

Europe

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type 

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Germany

U.K.

France

Italy

Spain

Rest of Europe

South America

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type  

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Brazil

Argentina

Rest of South America

Asia Pacific

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type 

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

China

India

Japan

Australia

Rest of Asia Pacific

Middle East and Africa

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type 

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Hepatitis A Vaccine Market - Competitive Landscape

Competitive Scenario

Market Positioning/Share Analysis

Mergers and Acquisitions Analysis

Hepatitis A Vaccine Market- Company Profiles

GlaxoSmithKline*

Company Overview

Product Type Portfolio and Description

Key Highlights

Financial Overview

Merck & Co., Inc.

Sanofi

Sinovac

Zhejiang Pukang

Changchun Institute of Biological

KM Biologics

IMBCA

ChangSheng

Convac (List Not Exhaustive)

Hepatitis A Vaccine Market - Premium Insights

Hepatitis A Vaccine Market - DataM Intelligence Analysis

Appendix

About Us and Services

Contact Us